CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Infliximab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01144143
NCT01144143Phase 4Completed
CompareCT.gov

Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

Herbert Lindsley, MD·interventional·Posted Jun 15, 2010·Updated Feb 8, 2018

In Brief

A Phase 4 clinical trial evaluating Infliximab, Placebo, and 1 other intervention for Osteoarthritis of the Knee. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if an anti-inflammatory drug, called infliximab, will reduce inflammation in the synovial lining in patients with an early stage of osteoarthritis of the knee. It will also help determine if the study medication decreases the accumulation of synovial fluid and prevents cartilage breakdown.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
CollaboratorsCentocor, Inc.

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 15, 2010
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.0 years ago

Interventions

Infliximabdrug

the study drug will be injected into the joint through a needle

Placebodrug

the placebo will be injected into the joint through a needle

Standard of Care: Methylprednisolone acetatedrug

Methylprednisolone acetate will be injected into the joint through a needle